Ocugen Inc (OCGN) - Total Liabilities
Based on the latest financial reports, Ocugen Inc (OCGN) has total liabilities worth $51.10 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ocugen Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Ocugen Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Ocugen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ocugen Inc balance sheet assets.
Ocugen Inc Competitors by Total Liabilities
The table below lists competitors of Ocugen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KG Mobility Corp.
KO:003620
|
Korea | ₩2.07 Trillion |
|
Stillfront Group AB (publ)
ST:SF
|
Sweden | Skr7.04 Billion |
|
Santana Minerals Ltd
AU:SMI
|
Australia | AU$5.18 Million |
|
Revenio Group Corporation
HE:REG1V
|
Finland | €30.90 Million |
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
China | CN¥1.17 Billion |
|
Joy Kie Corporation Limited.
SHE:300994
|
China | CN¥938.68 Million |
|
Parpro Corp
TW:4916
|
Taiwan | NT$1.92 Billion |
|
CPH Chemie und Papier Holding
SW:CPHN
|
Switzerland | CHF182.58 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Ocugen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OCGN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocugen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocugen Inc (2012–2025)
The table below shows the annual total liabilities of Ocugen Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $55.68 Million | +5.44% |
| 2024-12-31 | $52.81 Million | +120.20% |
| 2023-12-31 | $23.98 Million | -30.79% |
| 2022-12-31 | $34.65 Million | +248.50% |
| 2021-12-31 | $9.94 Million | +70.67% |
| 2020-12-31 | $5.83 Million | +0.64% |
| 2019-12-31 | $5.79 Million | -67.63% |
| 2018-12-31 | $17.89 Million | -19.80% |
| 2017-12-31 | $22.30 Million | -0.92% |
| 2016-12-31 | $22.51 Million | +162.12% |
| 2015-12-31 | $8.59 Million | -23.95% |
| 2014-12-31 | $11.29 Million | -87.50% |
| 2013-12-31 | $90.35 Million | +121.69% |
| 2012-12-31 | $40.76 Million | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more